Full Breakdown
BrainCo Raises $280 Million to Push Non-Invasive Brain-Computer Interfaces
7/12/2026, 8:47:22 PM
Core Development and Funding
Hangzhou-based BrainCo, founded in 2015 out of the Harvard Innovation Labs, announced a 2 billion-yuan (? $280 million) financing round co-led by IDG Capital and Walden International, the venture firm founded by Intel CEO Lip-Bu Tan. The round follows FDA listings for the company’s bionic hands and legs, which translate residual nerve and muscle signals into finger and foot movements. BrainCo also markets a sleep-aid headset that delivers low-intensity electrical pulses to stimulate stress-relieving neurochemicals, and a medical-grade attention device called FocusJoy launched in January.
Background & Strategic Context
China’s latest Five-Year Plan designates brain-computer interfaces (BCI) as a strategic “future industry,” and seven ministries have issued an implementation plan targeting breakthroughs in electrodes, chips and integrated BCI products by 2027, with a goal of cultivating two to three globally competitive BCI firms by 2030. The policy backdrop contrasts with the U.S. approach, where companies such as Elon Musk’s Neuralink pursue invasive implants that require craniotomy and robotic surgery.
Key Figures & Groups
- Nyx He, senior vice president of BrainCo, outlines the company’s staged roadmap from medical-insurance markets to consumer electronics.
- Rui Ma, founder of Tech Buzz China, comments on the limits of current augmentation claims.
- Alex Zhavoronkov, CEO of Insilico Medicine, critiques non-invasive signal capture.
- Thomas Tsao, co-founder of Gobi Partners, highlights ultrasound-based BCI as a low-risk alternative.
Data & Statistics
- Funding: 2 billion yuan ($280 million).
- FDA approvals: bionic hands and legs listed for commercial use.
- Jefferies (July 8 report) identifies invasive implants and ultrasound methods as the “most promising” frontiers, noting BrainCo’s proprietary dry-electrode sensors and AI decoding algorithm as competitive advantages.
Official Statements & Responses
Chinese state-media commentary cites a Chinese Academy of Sciences researcher who envisions a trajectory from near-term medical applications to autonomous-driving and mass-market consumer products. Jefferies’ analysis underscores that clear performance improvements and consumer willingness to pay will determine which BCI approach dominates.
Criticism & Opposition
Industry skeptics argue that non-invasive BCIs struggle with noisy, low-amplitude signals, limiting accuracy compared with implanted electrodes. Alex Zhavoronkov likens the challenge to “trying to capture light in distant galaxies.” Others, such as Thomas Tsao, contend that ultrasound offers a “more holistic view of the brain without surgical risk,” suggesting a viable middle ground.
Conflicting Reports & Gaps
Analysts differ on the ultimate market size: Thomas Tsao describes it as “virtually impossible to quantify,” while Jefferies emphasizes the need for “clear improvements” to justify consumer adoption. No public estimates exist for projected revenue from BrainCo’s planned licensing of its BCI platform.
Verbatim Quotes
- “I don't think anyone is remotely close to realizing that ... . Augmentation is like sci-fi at this point.” — Rui Ma, founder, Tech Buzz China
- “Non-invasive is like trying to capture light in distant galaxies,” — Alex Zhavoronkov, CEO, Insilico Medicine
- “Thomas Tsao, cofounder of Gobi Partners, a venture capital firm that has invested in Gestala, said ultrasound-based approaches offer a more holistic view of the brain without surgical risk.” — Thomas Tsao, co-founder, Gobi Partners
- “We're seeing genuine demand from rehabilitation centers and individuals who need solutions today, not five years from now,” — BrainCo representative
Why It Matters
BrainCo’s non-invasive strategy could accelerate BCI adoption by bypassing surgical hurdles, lowering costs, and opening markets in developing economies. Success would position China as a leader in consumer-grade neurotechnology and challenge the U.S. narrative that invasive implants are the sole path to high-fidelity brain-machine interfaces.
What’s Next
Sources indicate that BrainCo has confidentially filed for a Hong Kong IPO with China International Capital Corp and UBS Group, a listing that could raise several hundred million dollars and test public-market valuation of non-invasive BCI technology. The company also plans to license its platform to third-party manufacturers as its largest future revenue driver.
